HealthBeacon SHA

Regulatory Filings • Sep 6, 2022

National Storage Mechanism | Additional information

RNS Number : 3305Y

HealthBeacon PLC

06 September 2022

HealthBeacon announces commercial partnership with American Pharmacists Association Foundation

Agreement enables novel medication adherence services in pharmacies across the U.S.

Dublin, 06 September 2022: Healthbeacon plc ("HealthBeacon"), the leading digital therapeutics company that develops products for managing medications for patients in the home, today announces a commercial partnership with the American Pharmacists Association Foundation ("APhA Foundation"). The partnership will enable patients to access enhanced medication use support through an integrated pharmacist offering with the HealthBeacon Injection Care Management System ("ICMS") products in community pharmacies across the United States.

Beginning in September, the partnership will enable pharmacies to offer HealthBeacon's technology to patients on injectable medications. This will support HealthBeacon's goal of achieving 100,000 patients using the HealthBeacon ICMS technology by Q1 2024.

The APhA Foundation is an affiliated non-profit of the American Pharmacists Association, the oldest, largest, national professional association of pharmacists in the U.S. The partnership will see the APhA Foundation integrate Pharmacist Support with the HealthBeacon ICMS technology to increase adherence and patient outcomes. HealthBeacon's Smart Sharps Bin, Companion App, Sustainable Waste Management and access to Data Dashboards and API data integration will be available under the partnership.

The APhA Foundation has developed a novel adherence service called THERxAPYTM which, in this initiative, integrates adherence monitoring with community pharmacy support. This program will be implemented with support from pharmaceutical companies and managed care plans that wish to encourage the success of patients' adherence with prescribed injectable medications. The HealthBeacon partnership will now see its technology integrated into the Foundation's THERxAPYTM service.

Welcoming the partnership, Jim Joyce, HealthBeacon CEO, said:

"The community pharmacy setting is an excellent location for patients to access innovative pharmacist delivered medication adherence support and tools. Today half of all patients fail to utilize their medications as prescribed, costing healthcare systems billions of avoidable costs and the patients their underlying health. Together we have developed a best-in-class tech and service offering to address this challenge and we are delighted to be working the APhA Foundation to make this a reality.  We believe this is a positive step in making our technology more accessible to patients across the United States and that it will provide us with a model to deploy in other markets in the future." 

Enthusiastically about the partnership, Benjamin Bluml, RPh, APhA Foundation Executive Director and SVP, Research & Innovation said:

"The evidence base supporting the role of the pharmacist in improving medication adherence through patient-centered, team-based care services is strong and continues to grow. We are committed to designing and implementing innovative solutions that improves the lives of those we serve! The APhA Foundation's research and innovation initiatives focus on demonstrating how pharmacists can improve healthcare. It aims to create a new medication use system where patients, pharmacists, physicians and other healthcare professionals collaborate in interprofessional way to improve the cost effectiveness and quality of patient health outcomes".

Enquiries:
HealthBeacon: Laurence Flavin	Investor.Relations@HealthBeacon.com
Goodbody (Euronext Listing Sponsor and Broker): David Kearney	+353 (1) 667 0420
Stephen Kane
Drury (Public Relations):
Cathal Barry	+353 (0) 87 227 9281
Paul Clifford	+353 (0)87 327 2161

About HealthBeacon

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company that develops products for managing medications for patients in the home. The HealthBeacon Injection Care Management System tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools, and artificial intelligence (AI) driven data analytics. The Company operates in 17 countries primarily across Europe, North America and the United Kingdom employs more than 60 people and has obtained more than 30 design and utility patents. Peer reviewed evidence demonstrated up to a 26% improvement in injectable medication adherence by patients using its technology. The Company's mission is to become the world's leading digital therapeutics platform for injectable medications.

About the American Pharmacists Association (APhA) Foundation

The American Pharmacists Association (APhA) Foundation, a 501(c)(3) charitable nonprofit organization based in Washington, D.C. works to design solutions to optimize medication use and optimize care delivery in America. The APhA Foundation is affiliated with the American Pharmacists Association, the oldest and largest national professional society of pharmacists in the United States established in 1852. The APhA Foundation's mission is to improve health by inspiring philanthropy, research and innovation that advances pharmacists' patient care services. For more information, please visit www.APhAFoundation.org.

About the American Pharmacists Association

The American Pharmacists Association is the only organization advancing the entire pharmacy profession. Its expert staff, and strong volunteer leadership, including many experienced pharmacists, allow it to deliver vital leadership to help pharmacists, pharmaceutical scientists, student pharmacists and pharmacy technicians find success and satisfaction in their work, while advocating for changes that benefit them, their patients and their communities. For more information, please visit www.Pharmacist.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISEUVRNRUVUKRAR